203 related articles for article (PubMed ID: 34327218)
1. Patiromer in a Patient with Severe Hyperkalemia on Incremental Hemodialysis with 1 Session per Week: A Case Report and Literature Review.
De La Flor JC; Deira J; Marschall A; Valga F; Linares T; Monzon T; Albarracín C; Ruiz E
Case Rep Nephrol Dial; 2021; 11(2):158-166. PubMed ID: 34327218
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review.
Beccari MV; Meaney CJ
Core Evid; 2017; 12():11-24. PubMed ID: 28356904
[TBL] [Abstract][Full Text] [Related]
3. Twice-Weekly Hemodialysis With Adjuvant Pharmacotherapy and Transition to Thrice-Weekly Hemodialysis: A Pilot Study.
Murea M; Patel A; Highland BR; Yang W; Fletcher AJ; Kalantar-Zadeh K; Dressler E; Russell GB
Am J Kidney Dis; 2022 Aug; 80(2):227-240.e1. PubMed ID: 34933066
[TBL] [Abstract][Full Text] [Related]
4. Current Management of Hyperkalemia in Patients on Dialysis.
Bansal S; Pergola PE
Kidney Int Rep; 2020 Jun; 5(6):779-789. PubMed ID: 32518860
[TBL] [Abstract][Full Text] [Related]
5. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
Palmer BF
Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
[TBL] [Abstract][Full Text] [Related]
6. Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients.
Kovesdy CP; Rowan CG; Conrad A; Spiegel DM; Fogli J; Oestreicher N; Connaire JJ; Winkelmayer WC
Kidney Int Rep; 2019 Feb; 4(2):301-309. PubMed ID: 30775627
[TBL] [Abstract][Full Text] [Related]
7. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
[TBL] [Abstract][Full Text] [Related]
8. A Real-World Experience of Hyperkalemia Management Using Sodium Zirconium Cyclosilicate in Chronic Hemodialysis: A Multicenter Clinical Audit.
Qu X; Hua Y; Khan BA
Cureus; 2023 Sep; 15(9):e45058. PubMed ID: 37829953
[TBL] [Abstract][Full Text] [Related]
9. Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis.
Bushinsky DA; Rossignol P; Spiegel DM; Benton WW; Yuan J; Block GA; Wilcox CS; Agarwal R
Am J Nephrol; 2016; 44(5):404-410. PubMed ID: 27784004
[TBL] [Abstract][Full Text] [Related]
10. Patiromer: a clinical review.
Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
[TBL] [Abstract][Full Text] [Related]
11. Patiromer for the treatment of hyperkalemia.
Colbert GB; Patel D; Lerma EV
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):563-570. PubMed ID: 32511052
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic Treatment of Chronic Hyperkalemia in Patients with Chronic Kidney Disease.
Kim GH
Electrolyte Blood Press; 2019 Jun; 17(1):1-6. PubMed ID: 31338108
[TBL] [Abstract][Full Text] [Related]
13. Controversies in Management of Hyperkalemia.
Long B; Warix JR; Koyfman A
J Emerg Med; 2018 Aug; 55(2):192-205. PubMed ID: 29731287
[TBL] [Abstract][Full Text] [Related]
14. New Treatment Options for Hyperkalemia in Patients with Chronic Kidney Disease.
Esposito P; Conti NE; Falqui V; Cipriani L; Picciotto D; Costigliolo F; Garibotto G; Saio M; Viazzi F
J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32707890
[TBL] [Abstract][Full Text] [Related]
15. A randomized study to compare oral potassium binders in the treatment of acute hyperkalemia.
Cañas AE; Troutt HR; Jiang L; Tonthat S; Darwish O; Ferrey A; Lotfipour S; Kalantar-Zadeh K; Hanna R; Lau WL
BMC Nephrol; 2023 Apr; 24(1):89. PubMed ID: 37016309
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the introduction of novel potassium binders in routine care; the Stockholm CREAtinine measurements (SCREAM) project.
Gonzalez-Ortiz A; Clase CM; Bosi A; Fu EL; Pérez-Guillé BE; Faucon AL; Evans M; Zoccali C; Carrero JJ
J Nephrol; 2024 Jan; ():. PubMed ID: 38236474
[TBL] [Abstract][Full Text] [Related]
17. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
[TBL] [Abstract][Full Text] [Related]
18. New drugs to prevent and treat hyperkalemia.
Lepage L; Desforges K; Lafrance JP
Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
[TBL] [Abstract][Full Text] [Related]
19. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer.
Epstein M; Pitt B
Expert Opin Pharmacother; 2016 Jul; 17(10):1435-48. PubMed ID: 27180623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
